Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database

Surgery (United States)

Volumn 160, Issue 4, 2016, Pages 1080-1096

  Shubert, Christopher R ^a   Bergquist, John R ^a   Groeschl, Ryan T ^a   Habermann, Elizabeth B ^a   Wilson, Patrick M ^a   Truty, Mark J ^a   Smoot, Rory L ^a   Kendrick, Michael L ^a   Nagorney, David M ^a   Farnell, Michael B ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DATA BASE; FEMALE; GASTRECTOMY; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREAS SURGERY; PANCREATICODUODENECTOMY; PARTIAL GASTRECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; SYSTEMIC THERAPY; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FACTUAL DATABASE; KAPLAN MEIER METHOD; MORTALITY; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE; UNITED STATES;

ADENOCARCINOMA; ADULT; AGED; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 84994378052     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2016.06.010     Document Type: Conference Paper

References (27)

1. 1 Parkin, D., Bray, F., Devesa, S., Cancer burden in the year 2000. The global picture. Eur J Cancer 37 (2001), 4–66.
2. 2 Rahib, L., Smith, B.D., Aizenberg, R., Rosenzweig, A.B., Fleshman, J.M., Matrisian, L.M., Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74 (2014), 2913–2921.
3. 3 Wagner, M., Redaelli, C., Lietz, M., Seiler, C.A., Friess, H., Büchler, M.W., Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91 (2004), 586–594.
4. 4 Bilimoria, K.Y., Bentrem, D.J., Ko, C.Y., Stewart, A.K., Winchester, D.P., Talamonti, M.S., National failure to operate on early stage pancreatic cancer. Ann Surg 246 (2007), 173–180.
5. 5 Moorcraft, S.Y., Khan, K., Peckitt, C., Watkins, D., Rao, S., Cunningham, D., et al. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. Clin Colorectal Cancer 13 (2014), 232–238.
6. 6 Peddi, P.F., Lubner, S., McWilliams, R., Tan, B.R., Picus, J., Sorscher, S.M., et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP 13 (2012), 497–501.
7. 7 Sadot, E., Doussot, A., O'Reilly, E.M., Lowery, M.A., Goodman, K.A., Do, R.K.G., et al. FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma. Ann Surg Oncol 22 (2015), 3512–3521.
8. 8 Khushman, M., Dempsey, N., Cudris Maldonado, J., Loaiza-Bonilla, A., Velez, M., Carcas, L., et al. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology 15 (2015), 667–673.
9. 9 Chandhok, N.S., Saif, M.W., Updates on the use of neoadjuvant therapy in borderline resectable pancreatic cancer. JOP 15 (2014), 91–94.
10. 10 Katz, M.H., Pisters, P.W., Evans, D.B., Sun, C.C., Lee, J.E., Fleming, J.B., et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206 (2008), 833–838.
11. 11 Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 (2011), 1817–1825.
12. 12 Conroy, T., Paillot, B., François, E., Bugat, R., Jacob, J.H., Stein, U., et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer–a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 23 (2005), 1228–1236.
13. 13 Ychou, M., Conroy, T., Seitz, J.F., Gourgou, S., Hua, A., Mery-Mignard, D., et al. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol 14 (2003), 481–489.
14. 14 Nitsche, U., Wenzel, P., Siveke, J.T., Braren, R., Holzapfel, K., Schlitter, A.M., et al. Resectability after first-line FOLFIRINOX in initially unresectable locally advanced pancreatic cancer: a single-center experience. Ann Surg Oncol 22:Suppl 3 (2015), S1212–S1220.
15. 15 Heinemann, V., Haas, M., Boeck, S., Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol 24 (2013), 2484–2492.
16. 16 Colbert, L.E., Hall, W.A., Nickleach, D., Switchenko, J., Kooby, D.A., Liu, Y., et al. Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. Cancer 120 (2014), 499–506.
17. 17 Kooby, D.A., Gillespie, T.W., Liu, Y., Byrd-Sellers, J., Landry, J., Bian, J., et al. Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base. Ann Surg Oncol 20 (2013), 3634–3642.
18. 18 Khanal, N., Upadhyay, S., Dahal, S., Bhatt, V.R., Silberstein, P.T., Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data Base. Ther Adv Med Oncol 7 (2015), 198–205.
19. 19 Dimou, F., Sineshaw, H., Parmar, A.D., Tamirisa, N.P., Jemal, A., Riall, T.S., Trends in receipt and timing of multimodality therapy in early-stage pancreatic cancer. J Gastrointest Surg 20 (2016), 93–103.
20. 20 Raigani, S., Ammori, J., Kim, J., Hardacre, J.M., Trends in the treatment of resectable pancreatic adenocarcinoma. J Gastrointest Surg 18 (2014), 113–123.
21. 21 Ferrone, C.R., Marchegiani, G., Hong, T.S., Ryan, D.P., Deshpande, V., McDonnell, E.I., et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261 (2015), 12–17.
22. 22 Estrella, J.S., Rashid, A., Fleming, J.B., Katz, M.H., Lee, J.E., Wolf, R.A., et al. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 118 (2012), 268–277.
23. 23 Christians, K.K., Tsai, S., Mahmoud, A., Ritch, P., Thomas, J.P., Wiebe, L., et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?. Oncologist 19 (2014), 266–274.
24. 24 Artinyan, A., Anaya, D.A., McKenzie, S., Ellenhorn, J.D.I., Kim, J., Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer 117 (2011), 2044–2049.
25. 25 Belli, C., Cereda, S., Anand, S., Reni, M., Neoadjuvant therapy in resectable pancreatic cancer: a critical review. Cancer Treat Rev 39 (2013), 518–524.
26. 26 Heestand, G.M., Murphy, J.D., Lowy, A.M., Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol 33 (2015), 1770–1778.
27. 27 Katz, M.H., Crane, C.H., Varadhachary, G., Management of borderline resectable pancreatic cancer. Semin Radiat Oncol 24 (2014), 105–112.